An observational study in Oral Neoplasm, sponsored by Proteocyte Diagnostics Inc.. Recruiting at 3 sites in Canada. Open to participants aged 15 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-07.
Sponsored by Proteocyte Diagnostics Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Mouth Neoplasms with a site in Canada — 7 open to participants now, 9 under way, 1 of them phase 3. Mouth Neoplasms · Canada.
Among the 23 studies in Mouth Neoplasms with a site in Canada, this one is the only one that started in 2015, is one of 3 observational ones, and was the 17th registered.
447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.
Browse Mouth Neoplasms studies →7 of the 23 studies in Mouth Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18–65
University of British Columbia · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 18+
National Cancer Institute (NCI) · Sites in Canada, United States
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 97 Mouth Neoplasms studies recruiting now, 58 (60%) set no upper age limit and 23 (24%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 15 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 5 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 100 across 114 observational studies indexed under Mouth Neoplasms.
Median enrollment 40 across the 18 interventional studies, 500 across the 3 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 23 have an industry lead sponsor. The 10 most frequent:
Proteocyte Diagnostics Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Proteocyte Diagnostics Inc. has 1 study filed under Mouth Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Mouth Neoplasms with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05172245National Cancer Institute (NCI)Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | 2027-07-01 |
| NCT05429099University of British ColumbiaMandibular Reconstruction Preplanning (ViPMR) | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Mouth Neoplasms with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.
Background: The standard of care for potentially premalignant oral epithelial lesion (PPOEL) risk assessment for progression to cancer is dysplasia grading by histopathology. With significant overlap between dysplasia grades and high inter- and intra-observer variations, dysplasia grading alone has been shown to be inadequate as a prognostic tool. To investigate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in the early diagnosis of invasive oral cancer, a prospective multi-center observational study was designed with specimens obtained from community-based practices.
Methods: Patients that qualify to enroll in the study will be assessed for both standard of care histopathological assessment for dysplasia grade and STRATICYTE risk assessment, and followed for up to 60 months (from initial biopsy) to determine the outcome of their oral lesion(s).
The study population will be selected from community-based Oral \& Maxillofacial Surgery practices in the provinces of Ontario and Alberta, Canada
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No evidence of dysplasia Mild dysplasia Moderate dysplasia Severe dysplasia
Procedure: Standard of Care Histopathology · Procedure: STRATICYTE Assessment
Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer
Also known as: H&E assessment for dysplasia grade
Assessment for risk of progression to oral cancer
Also known as: S100A7 Immunohistochemistry Signature-based Assessment
Malignant Transformation Rate: Dysplasia
Cancer progression rate in patients with oral neoplasia with dysplasia and STRATICYTE Low-Risk or Elevated Risk
Time frame: 60 months
Malignant Transformation Rate: No Dysplasia
Cancer progression rate in patients with oral neoplasia without dysplasia and STRATICYTE Low-Risk or Elevated-Risk
Time frame: 60 months
Recurrence Rate
Recurrence rate in patients with oral neoplasia with or without dysplasia and STRATICYTE Low-Risk or Elevated-Risk
Time frame: 60 months
Plan to share: Undecided
Started Mar 2015 (actual). Primary completion is estimated for Dec 2025, 129 months after the start.
Of 48 observational studies under Mouth Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 216. This study's planned 129 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Proteocyte Diagnostics Inc.